MENLO PARK, Calif., May 25, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Jefferies Global Health Care Conference in New York City.

The presentation at the Jefferies conference is scheduled for 10:30 am EDT (7:30 am California time) on Monday, June 4, 2012.  The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcast will be archived for 30 days on the company's website.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

CONTACT:
August J. Moretti  
Depomed, Inc.
650-462-5900
amoretti@depomed.com

SOURCE Depomed, Inc.